Stammdaten
Bicara Therapeutics Inc. ist ein klinisches Biopharmazie-Unternehmen, das bifunktionelle Therapien für solide Tumoren entwickelt. Das Hauptprogramm ist ficerafusp alfa, ein bifunktionaler Antikörper, der einen auf den epidermalen Wachstumsfaktor-Rezeptor (EGFR) gerichteten monoklonalen Antikörper mit einer Domäne kombiniert, die an den humanen transformierenden Wachstumsfaktor Beta (TGF-β) bindet, zur Behandlung solider Tumoren. Das Unternehmen wurde 2018 gegründet und hat seinen Sitz in Boston, Massachusetts. Bicara Therapeutics Inc. ist eine Tochtergesellschaft von Biocon Limited. KI
Unternehmen & Branche
| Name | Bicara Therapeutics Inc. |
|---|---|
| Ticker | BCAX |
| CIK | 0002023658 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Biotechnologie (Forschung) |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 055477103 |
|---|---|
| ISIN | US0554771032 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,52 Bio. USD |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 116 HUNTINGTON AVENUE SUITE 703, 02116 BOSTON, MA |
| Telefon | 617-468-4219 |
| EIN (IRS) | 00-0000000 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Emerging growth company |
Bewertung
| KBV (P/B) | 3.787,66 |
|---|---|
| FCF-Rendite | 0,0 % |
Qualität & Bilanz
| ROIC | -34,2 % |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2023. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|
| Bewertung | |||||
| KBV (P/B) | – | 1,93 | 2,37 | 2.958,54 | |
| FCF-Rendite | – | -7,9 % | -11,2 % | 0,0 % | |
| Qualität & Bilanz | |||||
| ROIC | – | -13,8 % | -34,2 % | -30,5 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
BCAX
Bicara Therapeutics Inc.
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
39,2
24 neu, 59 erhöht, 274,5M $ netto
Aktivist
37,5
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 24.57 | +9.4 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 19.80 | +35.8 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 27.38 | EMA50: 25.51 | |
| MACD-Histogramm | Bärisch | 10 % | -0.396 | Bearisch | |
| RSI(14) | Neutral | 10 % | 49.6 | Neutral (30–70) | |
| Stoch %K(14) | Bullisch | 5 % | 10.9 | Überverkauft | |
| ADX(14)+DI | Neutral | 10 % | 22.0 | +DI: 15.3 / −DI: 19.0 | |
| Z-Score(60) | Neutral | 5 % | 0.77 | In Range | |
| 52W-Position | Bullisch | 5 % | 82.8 % | Hoch 30.40 / Tief 9.99 | |
| Bollinger(20,2σ) | Bullisch | 5 % | 10.2 % | Upper 30.22 / Mid 28.36 / Lower 26.50 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1562 | R²=0.61 / annualisiert +162.6 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-10 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -9.972 | 28,42 | -283.367,34 | -115,2% | |
| 2026-07-10 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -28 | 29,68 | -831,04 | -0,3% | |
| 2026-07-09 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -536 | 29,00 | -15.544,00 | -6,3% | |
| 2026-07-08 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -1.075 | 30,35 | -32.631,52 | -13,3% | |
| 2026-07-08 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -22.757 | 28,60 | -650.895,71 | -264,7% | |
| 2026-07-08 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -4.413 | 29,82 | -131.615,96 | -53,5% | |
| 2026-07-08 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -830 | 30,31 | -25.160,29 | -10,2% | |
| 2026-07-08 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -22.833 | 28,76 | -656.651,96 | -267,0% | |
| 2026-07-08 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.306 | 29,80 | -128.302,01 | -52,2% | |
| 2026-05-21 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9.200 | 20,42 | -187.883,32 | -76,4% | |
| 2026-05-18 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -12.022 | 19,96 | -239.981,96 | -97,6% | |
| 2026-05-18 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -2.978 | 20,35 | -60.596,64 | -24,6% | |
| 2026-05-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 20,29 | -91.313,55 | -37,1% | |
| 2026-05-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 20,29 | -162.335,20 | -66,0% | |
| 2026-04-27 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5.500 | 22,88 | -125.830,10 | -51,2% | |
| 2026-04-21 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9.200 | 23,00 | -211.613,80 | -86,1% | |
| 2026-04-20 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -15.000 | 23,61 | -354.145,50 | -144,0% | |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 23,01 | -103.532,85 | -42,1% | |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 23,01 | -184.058,40 | -74,8% | |
| 2026-03-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5.500 | 18,95 | -104.229,40 | -42,4% | |
| 2026-03-23 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9.200 | 18,52 | -170.348,12 | -69,3% | |
| 2026-03-20 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -1.596 | 18,95 | -30.246,27 | -12,3% | |
| 2026-03-19 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -6.905 | 18,78 | -129.704,90 | -52,7% | |
| 2026-03-18 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -6.499 | 18,84 | -122.414,51 | -49,8% | |
| 2026-03-16 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 19,66 | -88.456,95 | -36,0% | |
| 2026-03-16 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 19,66 | -157.256,80 | -63,9% | |
| 2026-03-09 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -36.766 | 19,17 | -704.657,16 | -286,5% | |
| 2026-03-06 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -3.817 | 18,75 | -71.571,80 | -29,1% | |
| 2026-03-05 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -1.786 | 18,74 | -33.464,10 | -13,6% | |
| 2026-03-04 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -16.300 | 18,52 | -301.920,01 | -122,8% | |
| 2026-03-04 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -2.963 | 18,25 | -54.061,71 | -22,0% | |
| 2026-03-04 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -2.631 | 18,73 | -49.288,63 | -20,0% | |
| 2026-03-03 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -13.555 | 18,22 | -246.909,75 | -100,4% | |
| 2026-03-03 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -200 | 18,45 | -3.690,00 | -1,5% | |
| 2026-03-03 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 18,16 | -81.733,95 | -33,2% | |
| 2026-03-03 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -12.892 | 18,16 | -234.158,69 | -95,2% | |
| 2026-02-26 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Purchase | 300.000 | 16,00 | 4.800.000,00 | +1951,9% | |
| 2026-02-25 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -3.108 | 18,04 | -56.066,77 | -22,8% | |
| 2026-02-25 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -523 | 18,04 | -9.434,66 | -3,8% | |
| 2026-01-22 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -1.882 | 18,15 | -34.162,44 | -13,9% | |
| 2026-01-22 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -3.828 | 18,10 | -69.295,99 | -28,2% | |
| 2026-01-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -149 | 18,02 | -2.684,98 | -1,1% | |
| 2025-12-22 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9.200 | 18,31 | -168.491,56 | -68,5% | |
| 2025-12-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 18,68 | -84.077,10 | -34,2% | |
| 2025-12-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 18,68 | -149.470,40 | -60,8% | |
| 2025-11-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -4.594 | 18,84 | -86.561,99 | -35,2% | |
| 2025-11-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -906 | 18,84 | -17.071,21 | -6,9% | |
| 2025-11-24 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -41.163 | 18,86 | -776.428,85 | -315,7% | |
| 2025-11-24 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -17.795 | 18,55 | -330.093,69 | -134,2% | |
| 2025-11-24 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5.500 | 18,45 | -101.475,00 | -41,3% | |
| 2025-11-21 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -605 | 18,15 | -10.980,75 | -4,5% | |
| 2025-11-21 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 18,05 | -144.376,00 | -58,7% | |
| 2025-11-21 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 18,05 | -81.211,50 | -33,0% | |
| 2025-10-16 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -24.103 | 18,83 | -453.760,67 | -184,5% | |
| 2025-10-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 18,16 | -145.243,20 | -59,1% | |
| 2025-10-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 18,16 | -81.699,30 | -33,2% | |
| 2025-10-15 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -13.289 | 18,84 | -250.391,34 | -101,8% | |
| 2025-10-13 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -11.445 | 18,92 | -216.545,12 | -88,1% | |
| 2025-10-09 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -22.000 | 18,45 | -405.900,00 | -165,1% | |
| 2025-10-09 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -6.415 | 18,23 | -116.931,34 | -47,5% | |
| 2025-10-08 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -5.627 | 18,21 | -102.456,42 | -41,7% | |
| 2025-10-07 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 18,06 | -144.472,80 | -58,7% | |
| 2025-10-07 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -18.244 | 18,22 | -332.385,61 | -135,2% | |
| 2025-10-07 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -2.900 | 18,06 | -52.371,39 | -21,3% | |
| 2025-10-06 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -15.600 | 18,06 | -281.665,80 | -114,5% | |
| 2025-10-06 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -6.514 | 18,17 | -118.356,12 | -48,1% | |
| 2025-10-06 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -24.000 | 18,06 | -433.332,00 | -176,2% | |
| 2025-09-29 | Meisner Lara | Officer, Chief Legal Officer | Open Market Sale | -33.807 | 14,75 | -498.653,25 | -202,8% | |
| 2025-09-15 | Meisner Lara | Officer, Chief Legal Officer | Open Market Sale | -15.829 | 11,49 | -181.875,21 | -74,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 7.255.993 | 0 | 7.255.993 | 144.321.701 | Neu | +100,0% | |
| Siren, L.L.C. | 5.802.970 | 0 | 5.802.970 | 115.421.073 | Neu | +100,0% | |
| Vestal Point Capital, LP | 5.425.000 | 0 | 5.425.000 | 107.903.250 | Neu | +100,0% | |
| Red Tree Management, LLC | 3.163.517 | 3.170.509 | -6.992 | 93.924.820 | Reduziert | -0,2% | |
| Deep Track Capital, LP | 4.062.500 | 0 | 4.062.500 | 80.803.125 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 3.339.218 | 0 | 3.339.218 | 66.350.262 | Neu | +100,0% | |
| TPG GP A, LLC | 3.010.425 | 0 | 3.010.425 | 59.877.353 | Neu | +100,0% | |
| BlackRock, Inc. | 2.843.707 | 0 | 2.843.707 | 56.561.328 | Neu | +100,0% | |
| Omega Fund Management, LLC | 2.392.150 | 0 | 2.392.150 | 47.579.864 | Neu | +100,0% | |
| Royalty Pharma Sub-Manager, LLC | 2.388.150 | 0 | 2.388.150 | 46.688.333 | Neu | +100,0% | |
| FMR LLC | 2.100.929 | 0 | 2.100.929 | 41.787.477 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.774.220 | 0 | 1.774.220 | 35.289.236 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1.726.242 | 0 | 1.726.242 | 34.334.954 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 1.621.643 | 0 | 1.621.643 | 32.254.484 | Neu | +100,0% | |
| STATE STREET CORP | 1.419.388 | 0 | 1.419.388 | 28.231.627 | Neu | +100,0% | |
| Jones Hill Capital LP | 1.260.136 | 0 | 1.260.136 | 25.064.105 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 830.906 | 0 | 830.906 | 16.530.951 | Neu | +100,0% | |
| FIL Ltd | 679.904 | 0 | 679.904 | 13.523.291 | Neu | +100,0% | |
| ORBIMED ADVISORS LLC | 667.300 | 0 | 667.300 | 13.272.597 | Neu | +100,0% | |
| ACORN CAPITAL ADVISORS, LLC | 643.382 | 0 | 643.382 | 12.796.860 | Neu | +100,0% | |
| NAN FUNG TRINITY (HK) Ltd | 427.885 | 427.885 | 0 | 12.703.906 | Unverändert | 0,0% | |
| Aisling Capital Management LP | 568.919 | 0 | 568.919 | 11.315.799 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 558.964 | 0 | 558.964 | 11.117.794 | Neu | +100,0% | |
| Palo Alto Investors LP | 550.408 | 0 | 550.408 | 10.947.615 | Neu | +100,0% | |
| Rock Springs Capital Management LP | 489.095 | 0 | 489.095 | 9.728.100 | Neu | +100,0% | |
| DAFNA Capital Management LLC | 421.733 | 0 | 421.733 | 8.388.269 | Neu | +100,0% | |
| MORGAN STANLEY | 421.219 | 0 | 421.219 | 8.378.047 | Neu | +100,0% | |
| Ensign Peak Advisors, Inc | 401.444 | 0 | 401.444 | 7.984.721 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 327.989 | 0 | 327.989 | 6.523.702 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 289.221 | 0 | 289.221 | 5.752.600 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 276.943 | 0 | 276.943 | 5.508.396 | Neu | +100,0% | |
| TD ASSET MANAGEMENT INC | 269.718 | 0 | 269.718 | 5.364.691 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 263.985 | 0 | 263.985 | 5.250.662 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 255.571 | 0 | 255.571 | 5.083.308 | Neu | +100,0% | |
| Candriam S.C.A. | 238.822 | 0 | 238.822 | 4.750.170 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 233.703 | 0 | 233.703 | 4.648.353 | Neu | +100,0% | |
| Woodline Partners LP | 232.690 | 0 | 232.690 | 4.628.204 | Neu | +100,0% | |
| Atle Fund Management AB | 145.657 | 1.169.634 | -1.023.977 | 4.324.556 | Reduziert | -87,5% | |
| UBS Group AG | 179.491 | 0 | 179.491 | 3.570.076 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 156.702 | 0 | 156.702 | 3.116.803 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 131.656 | 0 | 131.656 | 2.618.637 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 118.544 | 0 | 118.544 | 2.357.840 | Neu | +100,0% | |
| Napean Trading & Investment Co (Singapore) PTE Ltd | 113.780 | 0 | 113.780 | 2.263.084 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 109.261 | 0 | 109.261 | 2.170.202 | Neu | +100,0% | |
| Walleye Capital LLC | 108.008 | 0 | 108.008 | 2.148.279 | Neu | +100,0% | |
| Burkehill Global Management, LP | 100.000 | 0 | 100.000 | 1.989.000 | Neu | +100,0% | |
| ALPS ADVISORS INC | 66.182 | 51.580 | 14.602 | 1.964.944 | Aufgestockt | +28,3% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 90.285 | 0 | 90.285 | 1.795.769 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 89.881 | 0 | 89.881 | 1.787.733 | Neu | +100,0% | |
| Caption Management, LLC | 67.600 | 0 | 67.600 | 1.344.564 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Red Tree Management, LLC | 3.163.517 | 3.170.509 | -0,2% | 93.924.820 | 82,03 | 100 % | 7 Q |
| NAN FUNG TRINITY (HK) Ltd | 427.885 | 427.885 | 0,0% | 12.703.906 | 11,09 | 100 % | 5 Q |
| Atle Fund Management AB | 145.657 | 1.169.634 | -87,5% | 4.324.556 | 3,78 | 100 % | 6 Q |
| ALPS ADVISORS INC | 66.182 | 51.580 | +28,3% | 1.964.944 | 1,72 | 100 % | 5 Q |
| NEW YORK STATE COMMON RETIREMENT FUND | 15.500 | 7.500 | +106,7% | 460.195 | 0,40 | 100 % | 7 Q |
| Police & Firemen's Retirement System of New Jersey | 13.034 | 9.836 | +32,5% | 386.979 | 0,34 | 100 % | 7 Q |
| China Universal Asset Management Co., Ltd. | 10.457 | 11.244 | -7,0% | 310.468 | 0,27 | 100 % | 3 Q |
| NORDEN GROUP LLC | 8.911 | 0 | +100,0% | 264.567 | 0,23 | 100 % | 1 Q |
| Mirae Asset Global Investments Co., Ltd. | 2.939 | 3.305 | -11,1% | 87.259 | 0,08 | 100 % | 3 Q |
| GAMMA Investing LLC | 1.465 | 1.400 | +4,6% | 43.496 | 0,04 | 100 % | 7 Q |
| Versant Capital Management, Inc | 434 | 434 | 0,0% | 12.885 | 0,01 | 100 % | 5 Q |
| Sterling Capital Management LLC | 249 | 1.000 | -75,1% | 7.393 | 0,01 | 0 % | 7 Q |
| PRIVATE TRUST CO NA | 225 | 225 | 0,0% | 6.680 | 0,01 | 100 % | 4 Q |
| Farther Finance Advisors, LLC | 195 | 80 | +143,8% | 5.790 | 0,01 | 0 % | 5 Q |
| EverSource Wealth Advisors, LLC | 40 | 315 | -87,3% | 1.188 | 0,00 | 100 % | 6 Q |
| CoreCap Advisors, LLC | 32 | 32 | 0,0% | 950 | 0,00 | 0 % | 4 Q |
| True Wealth Design, LLC | 23 | 23 | 0,0% | 683 | 0,00 | 0 % | 6 Q |
| SJS Investment Consulting Inc. | 23 | 0 | +100,0% | 683 | 0,00 | 0 % | 1 Q |
| Hughes Financial Services, LLC | 1 | 0 | +100,0% | 30 | 0,00 | 100 % | 1 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 19 | 3,9 | 115 |
| 31.03.2026 | ✓ | 146 | 76,7 | 1.337 |
| 31.12.2025 | ✓ | 140 | 59,1 | 930 |
| 30.09.2025 | ✓ | 112 | 50,7 | 20.075 |
| 30.06.2025 | ✓ | 104 | 51,0 | 11.816 |
| 31.03.2025 | ✓ | 91 | 52,9 | 14.052 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Jones Hill Capital LP | 1.260.136 | 25.064.105 |
| Candriam S.C.A. | 238.822 | 4.750.170 |
| Walleye Capital LLC | 108.008 | 2.148.279 |
| Burkehill Global Management, LP | 100.000 | 1.989.000 |
| SEVEN GRAND MANAGERS, LLC | 62.500 | 1.243.125 |
| MARTINGALE ASSET MANAGEMENT L P | 57.538 | 1.144.431 |
| Swiss Life Asset Management Ltd | 8.651 | 978.718 |
| PRUDENTIAL FINANCIAL INC | 27.330 | 543.594 |
| Optimize Financial Inc | 23.996 | 477.280 |
| BALYASNY ASSET MANAGEMENT L.P. | 21.797 | 433.542 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 6.605.780 | 3.369.185 | +104.1 % | 131.389 |
| Vestal Point Capital, LP | 5.425.000 | 1.850.000 | +51.7 % | 107.903.250 |
| Deep Track Capital, LP | 4.062.500 | 1.448.496 | +55.4 % | 80.803.125 |
| Royalty Pharma Sub-Manager, LLC | 2.388.150 | 1.125.000 | +89.1 % | 46.688.333 |
| Atle Fund Management AB | 1.169.634 | 1.058.271 | +950.3 % | 2.315.235 |
| CITADEL ADVISORS LLC | 1.659.342 | 887.084 | +114.9 % | 33.004.313 |
| Janus Henderson Group Ltd. | 3.339.218 | 692.933 | +26.2 % | 66.350.262 |
| Siren, L.L.C. | 5.802.970 | 586.001 | +11.2 % | 115.421.073 |
| ORBIMED ADVISORS LLC | 667.300 | 458.200 | +219.1 % | 13.272.597 |
| BlackRock, Inc. | 2.843.707 | 315.256 | +12.5 % | 56.561.328 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| FMR LLC | 2.100.929 | -1.246.294 | -37.2 % | 41.787.477 |
| MILLENNIUM MANAGEMENT LLC | 156.702 | -277.997 | -64.0 % | 3.116.803 |
| STATE STREET CORP | 1.419.388 | -230.149 | -14.0 % | 28.231.627 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.376.198 | -183.337 | -11.8 % | 27.374 |
| FIL Ltd | 679.904 | -78.589 | -10.4 % | 13.523.291 |
| BARCLAYS PLC | 28.823 | -74.418 | -72.1 % | 573.289 |
| CITIGROUP INC | 9.585 | -57.112 | -85.6 % | 190.645 |
| BNP PARIBAS FINANCIAL MARKETS | 40.396 | -55.505 | -57.9 % | 803.476 |
| Russell Investments Group, Ltd. | 19.893 | -36.705 | -64.9 % | 395.670 |
| Rafferty Asset Management, LLC | 38.003 | -21.816 | -36.5 % | 755.880 |
Zusätzlich aktuell von 90 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 27.07.2026 | BlackRock, Inc. | Passiv (13G) | 5,40 % | 3.536.271 | Neu | |
| 15.05.2026 | JANUS HENDERSON GROUP PLC | Passiv (13G) | 5,10 % | 3.339.218 | Neu | |
| 15.05.2026 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G/A) | 6,21 % | 4.062.500 | +1,19 pp | |
| 15.05.2026 | Vestal Point Capital, LP (+1) | Passiv (13G/A) | 8,30 % | 5.425.000 | +1,80 pp | |
| 09.05.2026 | Red Tree Venture Fund, L.P. (+2) | Passiv (13G/A) | 4,80 % | 3.170.509 | -1,00 pp | |
| 06.05.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 3,20 % | 2.100.929 | -2,90 pp | |
| 08.04.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 10,10 % | 6.605.780 | +4,20 pp | |
| 02.03.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 7,30 % | 4.603.418 | -0,60 pp | |
| 02.03.2026 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 11,50 % | 7.279.739 | -1,30 pp | |
| 17.02.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 5,90 % | 3.236.595 | Neu | |
| 17.02.2026 | Vestal Point Capital, LP (+1) | Passiv (13G/A) | 6,50 % | 3.575.000 | -2,70 pp | |
| 12.02.2026 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G) | 5,02 % | 2.750.000 | Neu | |
| 05.02.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 6,10 % | 3.347.223 | +1,00 pp | |
| 14.08.2025 | Vestal Point Capital, LP (+1) | Passiv (13G/A) | 9,20 % | 5.000.000 | +4,10 pp | |
| 31.07.2025 | Avicenna Life Sci Master Fund LP (+2) | Passiv (13G/A) | 0,70 % | 355.025 | +0,60 pp | |
| 31.07.2025 | Invus Public Equities Advisors, LLC (+3) | Passiv (13G/A) | 8,90 % | 4.861.944 | +3,30 pp | |
| 31.07.2025 | Raymond Debbane | Passiv (13G/A) | 9,60 % | 5.216.969 | +3,90 pp | |
| 17.07.2025 | Abigail P. Johnson (+1) | Passiv (13G) | 5,10 % | 2.756.217 | +0,40 pp | |
| 17.07.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 4,70 % | 2.538.404 | -1,90 pp | |
| 15.05.2025 | Vestal Point Capital, LP (+1) | Passiv (13G) | 5,10 % | 2.768.975 | Neu | |
| 12.05.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 6,60 % | 3.611.573 | +1,40 pp | |
| 03.03.2025 | Abigail P. Johnson (+1) | Passiv (13G) | 5,20 % | 2.803.807 | +1,30 pp | |
| 12.02.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 3,90 % | 2.117.088 | Neu | |
| 26.09.2024 | Raymond Debbane | Passiv (13G) | 5,70 % | 3.072.827 | Neu | |
| 26.09.2024 | Invus Public Equities Advisors, LLC (+3) | Passiv (13G) | 5,60 % | 3.041.286 | Neu | |
| 26.09.2024 | Avicenna Life Sci Master Fund LP (+2) | Passiv (13G) | 0,10 % | 31.541 | Neu | |
| 26.09.2024 | Red Tree Venture Fund, L.P. (+2) | Passiv (13G) | 5,80 % | 3.170.509 | Neu | |
| 23.09.2024 | Longitude Prime Partners, LLC (+1) | Aktivist (13D) | 1,90 % | 774.530 | Neu | |
| 23.09.2024 | Longitude Venture Partners IV, L.P. (+1) | Aktivist (13D) | 4,10 % | 1.727.404 | Neu | |
| 23.09.2024 | Juliet Tammenoms Bakker (+1) | Aktivist (13D) | 6,00 % | 2.501.934 | Neu | |
| 23.09.2024 | RA Capital Management, L.P. (+2) | Aktivist (13D) | 12,80 % | 6.955.993 | Neu | |
| 23.09.2024 | RA Capital Healthcare Fund, L.P. | Aktivist (13D) | 7,90 % | 4.303.418 | Neu | |
| 23.09.2024 | Enavate Sciences GP, LLC (+1) | Aktivist (13D) | 9,00 % | 3.761.359 | Neu | |
| 18.09.2024 | James G. Coulter (+3) | Aktivist (13D) | 5,50 % | 3.010.425 | Neu |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -56.211.000 $ | -0,93 $ | 553.599.000 $ | 513.958.000 $ |
| 2025-12-31 | 10-K | – | -137.950.000 $ | -2,52 $ | 430.994.000 $ | 401.452.000 $ |
| 2025-09-30 | 10-Q | – | -36.330.000 $ | -0,67 $ | 424.688.000 $ | 402.780.000 $ |
| 2025-06-30 | 10-Q | – | -27.388.000 $ | -0,50 $ | 453.587.000 $ | 435.196.000 $ |
| 2025-03-31 | 10-Q | – | -36.846.000 $ | -0,68 $ | 478.077.000 $ | 458.957.000 $ |
| 2024-12-31 | 10-K | – | -67.995.000 $ | -4,05 $ | 509.996.000 $ | 491.875.000 $ |
| 2024-09-30 | 10-Q | – | -17.481.000 $ | -1,60 $ | 524.173.000 $ | 509.555.000 $ |
| 2024-06-30 | 10-Q | – | -17.049.000 $ | -19,01 $ | – | -174.776.000 $ |
| 2024-03-31 | 10-Q | – | -12.508.000 $ | -18,94 $ | – | -160.080.000 $ |
| 2023-12-31 | 10-K | – | -51.985.000 $ | -89,61 $ | 233.982.000 $ | -148.769.000 $ |
| 2023-09-30 | 10-Q | – | -22.845.000 $ | -38,23 $ | – | -137.111.000 $ |
| 2023-06-30 | 10-Q | – | -9.288.000 $ | – | – | -114.817.000 $ |
| 2023-03-31 | 10-Q | – | -7.412.000 $ | – | – | -105.908.000 $ |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 11.05.2026 | – | -0,93 |
| Q3 2025 | 30.09.2025 | 10.11.2025 | – | -0,67 |
| Q2 2025 | 30.06.2025 | 12.08.2025 | – | -0,50 |
| Q1 2025 | 31.03.2025 | 13.05.2025 | – | -0,68 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | – | -1,60 |
| Q2 2024 | 30.06.2024 | 12.11.2024 | – | -19,01 |
| Q1 2024 | 31.03.2024 | 12.11.2024 | – | -18,94 |
| Q3 2023 | 30.09.2023 | 12.11.2024 | – | -38,23 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 11.05.2026 | 10-Q | 31.03.2026 | 41 Tage | SEC » |
| 30.03.2026 | 10-K | 31.12.2025 | 89 Tage | SEC » |
| 10.11.2025 | 10-Q | 30.09.2025 | 41 Tage | SEC » |
| 12.08.2025 | 10-Q | 30.06.2025 | 43 Tage | SEC » |
| 13.05.2025 | 10-Q | 31.03.2025 | 43 Tage | SEC » |
| 27.03.2025 | 10-K | 31.12.2024 | 86 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 26.02.2026 | Kapitalerhöhung | $150,0 Mio · $16,00/Aktie | SEC » |
| 24.02.2026 | Kapitalerhöhung | $150,0 Mio | SEC » |
| 26.11.2025 | Kapitalerhöhung | $150,0 Mio | SEC » |
| 13.09.2024 | Börsengang | $293,0 Mio · $18,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 27.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.04.2026 | HV-Einladung | 09.06.2026 Jahres-HV | 15.04.2026 | DEF 14A | SEC » |
| 25.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 25.04.2025 | HV-Einladung | 09.06.2025 Jahres-HV | 14.04.2025 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (28.07.2026)
HOCH Abgang Schlüsselpersonen (28.07.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 28.07.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 28.07.2026 | Personalwechsel | 0,15 | 55 | Bicara Therapeutics gab den Rücktritt von Board Member Kiran Mazumdar-Shaw und die Bestellung von Jeremy Bender, Ph.D. und Christy Oliger al… 🔒 | SEC |
| 10.06.2026 | HV-Abstimmung | 0,00 | 20 | Bicara Therapeutics hielt am 9. Juni 2026 die jährliche Aktionärsversammlung ab. Aktionäre stimmten über zwei Anträge ab. | SEC |
| 21.05.2026 | Sonstiges | 0,75 | 78 | Bicara Therapeutics meldet positive Phase-3-Ergebnisse für Ficerafusp Alfa Plus Pembrolizumab in der Behandlung von HPV-negativem Kopf- und … 🔒 | SEC |
| 11.05.2026 | Quartalszahlen | 0,00 | 45 | Bicara Therapeutics kündigte Finanzergebnisse für das Quartal bis 31. März 2026 an. Das Unternehmen veröffentlichte eine Pressemitteilung mi… 🔒 | SEC |
| 30.03.2026 | Quartalszahlen | 0,00 | 50 | Bicara Therapeutics gab am 30.03.2026 die Geschäftsergebnisse für das Geschäftsjahr und Quartal zum 31.12.2025 bekannt. | SEC |
| 26.02.2026 | Sonstiges | 0,00 | 10 | 8-K eingereicht; Item 2.02 furnishiert ohne konkrete Finanzresultate oder Material-Inhalte. | SEC |
| 19.02.2026 | Sonstiges | 0,75 | 70 | Bicara Therapeutics präsentierte positive klinische Daten für Ficerafusp Alfa mit tiefen, dauerhaften Reaktionen bei HPV-negativem Kopf-Hals… 🔒 | SEC |
| 12.01.2026 | Guidance-Update | 0,40 | 65 | Bicara Therapeutics kündigte die optimale Dosis aus der Phase-3-Studie an und gab einen Ausblick für 2026 ab. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 7.379 | 29,34 | 216.500 |
| 2026-06-29 | 1.095 | 26,87 | 29.423 |
| 2026-06-26 | 54 | 26,34 | 1.422 |
| 2026-06-22 | 17 | 23,23 | 395 |
| 2026-06-17 | 3.077 | 21,95 | 67.540 |
| 2026-06-15 | 23.822 | 21,69 | 516.699 |
| 2026-06-12 | 23.800 | 21,28 | 506.464 |
| 2026-06-10 | 256 | 20,56 | 5.263 |
| 2026-06-08 | 3.787 | 20,00 | 75.740 |
| 2026-06-04 | 171 | 20,00 | 3.420 |
| 2026-05-18 | 6.313 | 20,23 | 127.712 |
| 2026-05-08 | 21.400 | 23,09 | 494.126 |
| 2026-04-29 | 81 | 21,92 | 1.776 |
| 2026-04-28 | 2.498 | 22,48 | 56.155 |
| 2026-04-17 | 922 | 23,93 | 22.063 |
| 2026-04-14 | 747 | 22,14 | 16.539 |
| 2026-04-09 | 599 | 21,61 | 12.944 |
| 2026-04-06 | 10.004 | 21,47 | 214.786 |
| 2026-04-02 | 2.863 | 20,50 | 58.692 |
| 2026-03-31 | 22 | 19,04 | 419 |
| 2026-03-30 | 783 | 18,37 | 14.384 |
| 2026-03-27 | 955 | 18,92 | 18.069 |
| 2026-03-26 | 1.488 | 18,68 | 27.796 |
| 2026-03-24 | 8 | 18,39 | 147 |
| 2026-03-20 | 4.946 | 18,79 | 92.935 |
| 2026-03-17 | 113.444 | 19,40 | 2.200.814 |
| 2026-03-16 | 120 | 19,19 | 2.303 |
| 2026-03-13 | 812 | 19,21 | 15.599 |
| 2026-03-12 | 2.261 | 19,90 | 44.994 |
| 2026-03-11 | 100.235 | 20,06 | 2.010.714 |
| 2026-03-10 | 30.623 | 19,70 | 603.273 |
| 2026-03-09 | 260 | 18,47 | 4.802 |
| 2026-03-06 | 1.043 | 18,50 | 19.296 |
| 2026-03-05 | 3.082 | 18,54 | 57.140 |
| 2026-03-04 | 2 | 17,92 | 36 |
| 2026-02-26 | 2.161 | 17,51 | 37.839 |
| 2026-02-18 | 1.562 | 14,08 | 21.993 |
| 2026-02-12 | 20.057 | 14,80 | 296.844 |
| 2026-02-06 | 30.015 | 15,10 | 453.227 |
| 2026-02-05 | 25.000 | 16,37 | 409.250 |
| 2026-02-04 | 585 | 17,01 | 9.951 |
| 2026-02-02 | 1.357 | 16,80 | 22.798 |
| 2026-01-30 | 1.421 | 16,91 | 24.029 |
| 2026-01-29 | 348 | 16,59 | 5.773 |